Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill creates a new “priority research drug” designation for covered outpatient drugs first approved at least 10 years earlier that are being investigated for a new indication addressing a significant unmet need with high prevalence among federal program beneficiaries. It requires HHS to set a request/designation process (90 days to establish process, 60 days to decide on requests) and defines high prevalence as at least 33 percent of claims for the target population paid by specified federal programs.
Liberal-left emphasizes lost rebate protections and higher program costs.
Relative to its intended legislative type, this bill is a focused substantive amendment that clearly defines a new statutory category and prescribes eligibility criteria and short administrative timelines.
The bill creates a new “priority research drug” designation for covered outpatient drugs first approved at least 10 years earlier that are being investigated for a new indication addressing a significant unmet need with high prevalence among federal program beneficiaries.
It requires HHS to set a request/designation process (90 days to establish process, 60 days to decide on requests) and defines high prevalence as at least 33 percent of claims for the target population paid by specified federal programs.
Drugs so designated are excluded from statutory definitions of “line extension” for Medicaid and Medicare Part D rebate rules and from the Medicaid “best price” special rule for selected drugs.
Narrow but costly carve-out for manufacturers raises fiscal objections and stakeholder pushback despite potential industry support.
Relative to its intended legislative type, this bill is a focused substantive amendment that clearly defines a new statutory category and prescribes eligibility criteria and short administrative timelines. It integrates into specific statutory locations and unambiguously alters rebate/line‑extension treatment for designated drugs.
Liberal-left emphasizes lost rebate protections and higher program costs.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberal-left emphasizes lost rebate protections and higher program costs.
Skeptical overall.
While the policy could encourage repurposing older drugs for unmet needs, it removes rebate and best‑price protections that currently lower federal and state drug costs.
Absent safeguards, this may increase Medicare and Medicaid spending and patient cost-sharing.
Cautiously open.
The bill creates a clear incentive mechanism to repurpose older drugs, which could yield clinical benefits.
However, it also removes rebate triggers and best-price implications, raising legitimate fiscal concerns that warrant oversight and limits.
Generally supportive.
The bill lowers regulatory disincentives for manufacturers to investigate new uses of older drugs, fostering private-sector innovation and faster patient access.
The carve-outs reduce pricing penalties that can deter investment in repurposing.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow but costly carve-out for manufacturers raises fiscal objections and stakeholder pushback despite potential industry support.
The bill has not accumulated any surfaced votes yet.
Liberal-left emphasizes lost rebate protections and higher program costs.
Narrow but costly carve-out for manufacturers raises fiscal objections and stakeholder pushback despite potential industry support.
Relative to its intended legislative type, this bill is a focused substantive amendment that clearly defines a new statutory category and prescribes eligibility criteria and short administrative timelines. It integrates…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.